The spirits maker has landed itself in a cocktail of regulatory issues after it allegedly colluded with retailers to illegally boost sales of its products in the national capital
Subscribe to read this story
We publish over 500 original, detailed stories every year on startups, corporates, stock markets and economic current affairs.
Limited time offer $125 $99 for 1 year
The self-styled options queen pulled off a Rs 104 crore scam, masquerading as a trading expert to play on investor gullibility, with nary a peep out of SEBI for over 10 years. Will the scourge ever be eradicated?
While earlier attempts were unsuccessful, with Glenmark running into huge losses, there seems to be growing consensus that the drugmaker’s R&D strategy makes it a different company. Perhaps even a valuable one.
Mounting concentration risk has forced the fund house to change tack yet again. While shifting focus to small-cap stocks from defensive ones could somewhat help, such frequent switches are less than ideal.